
SECTION 1. This document establishes standards and protocols for physicians in the prescribing of controlled substances for pain management treatment. It is adopted under the authority of IC 25-22.5-13-2.

SECTION 2. (a) The definitions in this SECTION apply throughout this document.

(b) "Chronic pain" means a state in which pain persists beyond the usual course of an acute disease or healing of an injury, or that may or may not be associated with an acute or chronic pathologic process that causes continuous or intermittent pain over months or years.

(c) "Controlled substances" has the meaning set forth in IC 35-48-1-9.

(d) "Morphine equivalent dose" means a conversion of various opioids to a standardized dose of morphine by the use of accepted conversion tables.

(e) "Opioid" means any of various narcotics containing opium or one (1) or more of its natural or synthetic derivatives.

(f) "Outset of an opioid treatment plan" means that a patient has been prescribed opioids as described in SECTION 3(c) of this document, and, therefore, the provisions stated in SECTION 3(a) of this document become applicable to that patient.

(g) "Terminal" means a condition caused by injury, disease, or illness from which, to a reasonable degree of medical certainty:
   (1) there can be no recovery; and
   (2) progression to death can be anticipated as an eventual consequence of that condition.

SECTION 3. (a) This SECTION and SECTIONS 4 through 11 of this document establish requirements concerning the use of opioids for chronic pain management for patients.

(b) Notwithstanding subsection (a), this SECTION and SECTIONS 4 through 11 of this document shall not apply to the use of opioids for chronic pain management for the following:
   (1) Patients with a terminal condition.
   (2) Residents of a health facility licensed under IC 16-28.
   (3) Patients enrolled in a hospice program licensed under IC 16-25.
   (4) Patients enrolled in an inpatient or outpatient palliative care program of a hospital licensed under IC 16-21 or a hospice licensed under IC 16-25.

   However, a period of time that a patient who was, but is no longer, a resident or patient as described in subdivisions (2) through (4) shall be included in the calculations under subsection (c).

(c) The requirements in the SECTIONS identified in subsection (a) only apply if a patient has been prescribed:
   (1) more than sixty (60) opioid-containing pills a month; or
   (2) a morphine equivalent dose of more than fifteen (15) milligrams per day; for more than three (3) consecutive months.

(d) Because the requirements in the SECTIONS identified in subsection (a) do not apply until the time stated in subsection (c), the initial evaluation of the patient for the purposes of SECTIONS 4, 7(a), and 8(a) [of this document] shall not be required to take place until that time.

(e) Notwithstanding subsection (d), the physician may undertake those actions earlier than required if
the physician deems it medically appropriate and if those actions meet the requirements a further initial
evaluation is not required. If the physician’s conduct earlier than required under this
subsection, any subsequent requirements are determined by when the initial evaluation would have been
required and not at the earlier date it actually was conducted.

SECTION 4. (a) The physician shall do the physician’s own evaluation and risk stratification of the
patient by doing the following in the initial evaluation of the patient:
(1) Performing an appropriately focused history and physical exam and obtain or order appropriate
tests, as indicated.
(2) Making a diligent effort to obtain and review records from previous health care providers to
supplement the physician’s understanding of the patient’s chronic pain problem, including past
treatments, and documenting this effort.
(3) Asking the patient to complete an objective pain assessment tool to document and better
understand the patient’s specific pain concerns.
(4) Assessing both the patient’s mental health status and risk for substance abuse using available
validated screening tools.
(5) After completing the initial evaluation, establishing a working diagnosis and tailoring a treatment
plan to meaningful and functional goals with the patient reviewing them from time to time.

(b) Where medically appropriate, the physician shall utilize non-opioid options instead of or in
addition to prescribing opioids.

SECTION 5. The physician shall discuss with the patient the potential risks and benefits of opioid
treatment for chronic pain, as well as expectations related to prescription requests and proper medication
use. In doing so, the physician shall:
(1) Where alternative modalities to opioids for managing pain exist for a patient, discuss them with
the patient.
(2) Provide a simple and clear explanation to help patients understand the key elements of their
treatment plan.
(3) Counsel women between the ages of fourteen (14) and fifty-five (55) with child bearing potential
about the risks to the fetus when the mother has been taking opioids while pregnant. Such described
risks shall include fetal opioid dependency and neonatal abstinence syndrome (NAS).
(4) Together with the patient, review and sign a "Treatment Agreement", which shall include at least
the following:
(A) The goals of the treatment.
(B) The patient’s consent to drug monitoring testing.
(C) The physician’s prescribing policies, which must include at least:
   (i) a requirement that the patient take the medication as prescribed; and
   (ii) a prohibition of sharing medication with other individuals.
(D) A requirement that the patient inform the physician about any other controlled substances
   prescribed or taken.
(E) The granting of permission to the physician to conduct random pill counts.
(F) Reasons the opioid therapy may be changed or discontinued by the physician.
A copy of the treatment agreement shall be retained in the patient’s chart.

SECTION 6. (a) Physicians shall not prescribe opioids for patients without periodic scheduled visits.
Visits for patients with a stable medication regimen and treatment plan shall occur face to face at least
once every four (4) months. More frequent visits may be appropriate for patients working with the
physician to achieve optimal management. For patients requiring changes to the medication and
treatment plan, if changes are prescribed by the physician, the visits required by this subsection shall be
scheduled at least once every two (2) months until the medication and treatment has been stabilized.

(b) During the visits required by subsection (a), the physician shall evaluate patient progress and
compliance with the patient’s treatment plan regularly and set clear expectations along the way, such as
attending physical therapy, counseling, or other treatment options.

SECTION 7. At the outset of an opioid treatment plan, and at least annually thereafter, a physician
prescribing opioids for a patient shall run an INSPECT report on that patient under IC 35-48-7-11.1(d)(4)
and document in the patient’s chart whether the INSPECT report is consistent with the physician’s
knowledge of the patient’s controlled substance use history.
SECTION 8. (a) At the outset of an opioid treatment plan, and at least annually thereafter, a physician
prescribing opioids for a patient shall perform or order a drug monitoring test, which must include a
confirmatory test, on the patient.

(b) If the test required under subsection (a) reveals inconsistent medication use patterns or the
presence of illicit substances, a review of the current treatment plan shall be required. Documentation
of the revised plan and discussion with the patient must be recorded in the patient’s chart.

SECTION 9. When a patient’s opioid dose reaches a morphine equivalent dose of more than sixty (60)
milligrams per day, a face-to-face review of the treatment plan and patient evaluation must be scheduled,
including consideration of referral to a specialist. If the physician elects to continue providing opioid
therapy at a morphine equivalent dose of more than sixty (60) milligrams per day, the physician must
develop a revised assessment and plan for ongoing treatment. The revised assessment and plan must be
documented in the patient’s chart, including an assessment of increased risk for adverse outcomes,
including death, if the physician elects to provide ongoing opioid treatment.

SECTION 10. (a) IC 25-27.5-5 addresses the scope of practice of physician assistants in their
dependent practice under supervising physicians including limiting the duties and responsibilities of
physician assistants to those that are delegated by the supervising physician and that are within the
supervising physician's scope of practice. IC 25-27.5-6 addresses supervisory responsibilities of the
supervising physician, or when applicable, a physician designee. The prescribing of opioids for chronic
pain management as regulated by this document falls within the requirements on supervising physicians,
or when applicable, on physician designees, under IC 25-27.5-5 and IC 25-27.5-6 including appropriate
delegating of duties and responsibilities to physician assistants and appropriate supervision of physician
assistants.

(b) IC 25-23-1-19.4 through IC 25-23-1-19.8 and 848 IAC 5 address the practice of advanced practice
nurses with prescriptive authority in collaboration with a physician. The prescribing of opioids for
chronic pain management as regulated by this document falls within the requirements on collaborating
physicians regarding the prescriptive authority for advanced practice nurses under IC 25-23-1-19.4
though IC 25-23-1-19.8 and 848 IAC 5.

SECTION 11. (a) Initial running of an INSPECT report as required under SECTION 7 of this document
shall not be required for any patient who fell within the scope of SECTION 3(c) of this document before
December 15, 2013. Initial conducting of a drug monitoring test as required under SECTION 8(a) of this
document shall not be required for any patient who fell within the scope of SECTION 3(c) of this
document before January 1, 2015. However, all other requirements of this document apply to these
patients; that is, every requirement except for the initial running of the INSPECT report and the initial or
annual conducting of a drug monitoring test.

(b) Notwithstanding subsection (a) and SECTION 7 of this document, the first running of an annual
INSPECT report under SECTION 7 of this document shall not be required to be conducted before
November 1, 2014. Nothing about this subsection shall be construed to prohibit a physician from running
a report sooner than required by this subsection.

(c) Notwithstanding SECTION 8(a) of this document, the first conducting of an annual drug
monitoring test under SECTION 8(a) of this document shall not be required to be conducted before
January 1, 2015. Nothing about this subsection shall be construed to prohibit a physician from
conducting a test sooner than required by this subsection.

SECTION 12. SECTIONS 1 through 11 of this document take effect December 15, 2013.